Profil
Maureen Deehan is currently the Chief Executive Officer at Vivtex Corp.
She previously worked at Nordic Nanovector ASA as the Head of Corporate Development & Strategy.
She completed her undergraduate degree at the University of Strathclyde and holds a doctorate from the University of Glasgow School of Medicine.
Postes actifs de Maureen Deehan
| Sociétés | Poste | Début |
|---|---|---|
| Vivtex Corp. | Directeur Général | 21/02/2023 |
Anciens postes connus de Maureen Deehan
| Sociétés | Poste | Fin |
|---|---|---|
| THOR MEDICAL | Corporate Officer/Principal | - |
Formation de Maureen Deehan
| University of Glasgow School of Medicine | Doctorate Degree |
| University of Strathclyde | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
| Vivtex Corp. |
